Key clinical point: Several factors are significantly associated with lower odds of discontinuing immune suppression after allogeneic hematopoietic cell transplant.
Major finding: The factors include age older than 50 years (adjusted odds ratio, 0.27; P less than .001); having a mismatched, unrelated donor (aOR, 0.37; P = .008); receiving peripheral blood stem cells from an unrelated donor (aOR, 0.46; P less than .001), and having advanced stage disease (aOR, 0.45; P = .002).
Study details: An analysis of two phase 3 trials including a total of 827 patients.
Disclosures: The study was funded by the National Heart Lung and Blood Institute. Two of the researchers reported relationships with more than 30 pharmaceutical companies.
Pidala J et al. JAMA Oncol. 2019 Sep 26. doi: 10.1001/jamaoncol.2019.2974.